Mentice

The order includes the delivery of simulation systems as part of a two-year service agreement to support physician and internal personnel training for structural heart therapies. The systems will facilitate technical and procedural training, addressing the clinical need for physician proficiency in advanced therapies to support improved patient outcomes. The agreement also includes a renewed software license to optimize the training platform.

Structural heart therapies, such as left atrial appendage occlusion, are essential for addressing stroke prevention in atrial fibrillation (AF) patients who are unsuitable for long-term anticoagulation. AF, a condition that affects over 59.7 million patients globally[1], significantly increases the risk of stroke and other cardiovascular complications, emphasizing the need for standardized physician training to ensure safe adoption. With the structural heart market experiencing rapid growth, the demand for effective therapies and training solutions continues to rise[2].

Göran Malmberg, CEO of Mentice, commented, "This order highlights the continued need for innovative training solutions to support the adoption of life-saving advanced structural heart therapies. We are proud to strengthen our collaboration with this leading company in the MedTech field, helping physicians deliver safer, more effective patient care and addressing the need of a rapidly growing market."

The order will be accounted for in the order book for the business area of the Medical Device Industry during the fourth quarter of 2024, with the services deliveries during the coming calendar years.

References:
[1] heart.bmj.com
[2] https://www.grandviewresearch.com/industry-analysis/structural-heart-devices-market

Mentice definition of a Top 20 Medical Technology company can be found here: https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html.